An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adicet Bio to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Adicet Bio, Inc. (NASDAQ: ACET), a clinical-stage biotechnology firm, is advancing allogeneic gamma delta CAR T cell therapies for cancer. The company will participate in two investor conferences in April 2022. On April 14, CEO Chen Schor will join a panel at the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference. Additionally, Adicet's management will conduct 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami, Florida on April 27, 2022. These events showcase Adicet's commitment to innovative cancer therapy development.
Positive
None.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in April.
Details of the events are as follows:
Canaccord Genuity 2022 Horizons in Oncology Virtual Conference, April 14, 2022 Chen Schor, President and Chief Executive Officer, will participate in a panel discussion titled, “Gamma Delta T-cells: A differentiated approach” on Thursday, April 14, 2022, at 12:00 PM ET.
2022 Jefferies Biotech on the Bay Summit, April 26-27, 2022 Adicet’s management team will participate in 1x1 investor meetings at the St. Regis, Bal Harbour in Miami, Florida on April 27, 2022.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.
What conferences will Adicet Bio (ACET) participate in April 2022?
Adicet Bio will participate in the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference on April 14 and the Jefferies Biotech on the Bay Summit on April 26-27, 2022.
Who will represent Adicet Bio at the Canaccord Genuity conference?
CEO Chen Schor will participate in a panel discussion titled 'Gamma Delta T-cells: A differentiated approach' on April 14, 2022.
Where will Adicet Bio's management hold investor meetings?
Adicet Bio's management will hold 1x1 investor meetings at the St. Regis in Bal Harbour, Miami, Florida on April 27, 2022.
What is the focus of Adicet Bio's therapies?
Adicet Bio focuses on developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer treatment.
